Thu, Mar 5, 2015, 9:53 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Myriad Genetics Inc. Message Board

  • greendog03 greendog03 Dec 30, 2013 10:58 AM Flag

    Isn't this all old news which came out december 2nd

    December 2, 2013
    10:32 EDT MYGN, LH Myriad Genetics retreats after CMS announces new reimbursement rate
    Shares of Myriad Genetics (MYGN) are declining after the Centers for Medicare & Medicaid Services announced that it would pay a fee of $1,438 to Myriad for each beneficiary who undergoes its BRACAnalysis test. BRACAnalysis is used to identify people who, based on their genetic makeup, have a very high likelihood of developing breast and ovarian cancer. WHAT'S NEW: CMS stated that it would reimburse Myriad $1,438 for each beneficiary who undergoes BRACAnalysis.

34.79+0.49(+1.43%)Mar 5 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Geron Corporation
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orexigen Therapeutics, Inc.
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orbital ATK, Inc.
NYSEThu, Mar 5, 2015 4:02 PM EST